Stratification of Residual Risk of HCC Following HCV Clearance With Direct-Acting Antivirals in Patients With Advanced Fibrosis and Cirrhosis

Hepatology. 2020 Dec;72(6):1897-1899. doi: 10.1002/hep.31639.

Authors

V Wendy Setiawan^{1

2

3

4}, Hugo R Rosen^{2

3

4}

Affiliations

¹ Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA.
² Norris Comprehensive Cancer Center, Los Angeles, CA.
³ Department of Medicine, Keck School of Medicine, Los Angeles, CA.
⁴ Research Center for Liver Disease, University of Southern California, Los Angeles, CA.

PMID: 33205438
DOI: 10.1002/hep.31639

No abstract available

Publication types

Editorial
Research Support, N.I.H., Extramural
Comment

MeSH terms

Antiviral Agents / therapeutic use
Carcinoma, Hepatocellular* / drug therapy
Hepatitis C, Chronic* / complications
Hepatitis C, Chronic* / drug therapy
Humans
Liver Cirrhosis / drug therapy
Liver Neoplasms* / drug therapy
Risk Factors

Substances

Antiviral Agents

Grants and funding